242 related articles for article (PubMed ID: 33822479)
1. Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of lemborexant.
Dayal S; Aluri J; Hall N; Filippov G; Moline M; Reyderman L; Landry I
Pharmacol Res Perspect; 2021 Apr; 9(2):e00758. PubMed ID: 33822479
[TBL] [Abstract][Full Text] [Related]
2. Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexant.
Landry I; Aluri J; Hall N; Filippov G; Dayal S; Moline M; Reyderman L
Pharmacol Res Perspect; 2021 Apr; 9(2):e00734. PubMed ID: 33689224
[TBL] [Abstract][Full Text] [Related]
3. Population Pharmacokinetics and Exposure-Response Analyses for the Most Frequent Adverse Events Following Treatment With Lemborexant, an Orexin Receptor Antagonist, in Subjects With Insomnia Disorder.
Lalovic B; Majid O; Aluri J; Landry I; Moline M; Hussein Z
J Clin Pharmacol; 2020 Dec; 60(12):1642-1654. PubMed ID: 32666570
[TBL] [Abstract][Full Text] [Related]
4. Long-term effectiveness and safety of lemborexant in adults with insomnia disorder: results from a phase 3 randomized clinical trial.
Yardley J; Kärppä M; Inoue Y; Pinner K; Perdomo C; Ishikawa K; Filippov G; Kubota N; Moline M
Sleep Med; 2021 Apr; 80():333-342. PubMed ID: 33636648
[TBL] [Abstract][Full Text] [Related]
5. Effects of Lemborexant on the Pharmacokinetics of Oral Contraceptives: Results From a Phase 1 Drug-Drug Interaction Study in Healthy Females.
Landry I; Aluri J; Hall N; Filippov G; Dayal S; Moline M; Reyderman L
Clin Pharmacol Drug Dev; 2021 Sep; 10(9):1089-1098. PubMed ID: 34107159
[TBL] [Abstract][Full Text] [Related]
6. Respiratory Safety of Lemborexant in Healthy Subjects: A Single-Dose, Randomized, Double-Blind, Placebo-Controlled, Crossover Study.
Cheng JY; Moline M; Zammit GK; Filippov G; Bsharat M; Hall N
Clin Drug Investig; 2021 May; 41(5):449-457. PubMed ID: 33723806
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the CYP3A and CYP2B6 Drug-Drug Interaction Potential of Lemborexant.
Landry I; Aluri J; Nakai K; Hall N; Miyajima Y; Ueno T; Dayal S; Filippov G; Lalovic B; Moline M; Reyderman L
Clin Pharmacol Drug Dev; 2021 Jun; 10(6):681-690. PubMed ID: 33455055
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, Pharmacodynamics, and Safety of the Dual Orexin Receptor Antagonist Lemborexant: Findings From Single-Dose and Multiple-Ascending-Dose Phase 1 Studies in Healthy Adults.
Landry I; Nakai K; Ferry J; Aluri J; Hall N; Lalovic B; Moline ML
Clin Pharmacol Drug Dev; 2021 Feb; 10(2):153-165. PubMed ID: 32468649
[TBL] [Abstract][Full Text] [Related]
9. Lack of residual morning effects of lemborexant treatment for insomnia: summary of findings across 9 clinical trials.
Moline M; Zammit G; Yardley J; Pinner K; Kumar D; Perdomo C; Cheng JY
Postgrad Med; 2021 Jan; 133(1):71-81. PubMed ID: 33119423
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, safety, and tolerability of siponimod (BAF312) in subjects with different levels of hepatic impairment: a single-dose, open-label, parallel-group study
.
Shakeri-Nejad K; Aslanis V; Veldandi UK; Gardin A; Zaehringer A; Dodman A; Su Z; Legangneux E
Int J Clin Pharmacol Ther; 2017 Jan; 55(1):41-53. PubMed ID: 27443658
[TBL] [Abstract][Full Text] [Related]
11. Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study.
Yin OQ; Gallagher N; Tanaka C; Fisher D; Sethuraman V; Zhou W; Lin TH; Heuman D; Schran H
Clin Ther; 2009; 31 Pt 2():2459-69. PubMed ID: 20110053
[TBL] [Abstract][Full Text] [Related]
12. Effect of Liver Cirrhosis on the Pharmacokinetics, Metabolism, and Tolerability of Daridorexant, A Novel Dual Orexin Receptor Antagonist.
Berger B; Dingemanse J; Sabattini G; Delahaye S; Duthaler U; Muehlan C; Krähenbühl S
Clin Pharmacokinet; 2021 Oct; 60(10):1349-1360. PubMed ID: 34002356
[TBL] [Abstract][Full Text] [Related]
13. Disposition and metabolism of [
Ueno T; Ishida T; Kusano K
Xenobiotica; 2019 Jun; 49(6):688-697. PubMed ID: 29806508
[TBL] [Abstract][Full Text] [Related]
14. Disposition and Metabolism of [
Ueno T; Ishida T; Aluri J; Suzuki M; Beuckmann CT; Kameyama T; Asakura S; Kusano K
Drug Metab Dispos; 2021 Jan; 49(1):31-38. PubMed ID: 33144331
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, Safety, and Tolerability of Single Oral Doses of a Novel Oxytocin Receptor Antagonist-Cligosiban-in Development for Premature Ejaculation: Three Randomized Clinical Trials in Healthy Subjects.
Osterloh IH; Muirhead GJ; Sultana S; Whaley S; van den Berg F; Atiee G
J Sex Med; 2018 Nov; 15(11):1547-1557. PubMed ID: 30341006
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial.
Rosenberg R; Murphy P; Zammit G; Mayleben D; Kumar D; Dhadda S; Filippov G; LoPresti A; Moline M
JAMA Netw Open; 2019 Dec; 2(12):e1918254. PubMed ID: 31880796
[TBL] [Abstract][Full Text] [Related]
17. Influence of hepatic dysfunction on the pharmacokinetics and safety of fimasartan.
Kim CO; Lee HW; Oh ES; Seong SJ; Kim DY; Lee J; Ahn SH; Yoon YR; Cho CM; Park MS
J Cardiovasc Pharmacol; 2013 Dec; 62(6):524-9. PubMed ID: 24084213
[TBL] [Abstract][Full Text] [Related]
18. Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2.
Kärppä M; Yardley J; Pinner K; Filippov G; Zammit G; Moline M; Perdomo C; Inoue Y; Ishikawa K; Kubota N
Sleep; 2020 Sep; 43(9):. PubMed ID: 32585700
[TBL] [Abstract][Full Text] [Related]
19. Effect of hepatic impairment on the pharmacokinetics of vilaprisan: An open-label, single-dose, parallel-group study.
Chattopadhyay N; Riecke K; Ligges S; Zimmermann T; Halabi A; Schultze-Mosgau MH
Br J Clin Pharmacol; 2019 Sep; 85(9):2011-2021. PubMed ID: 31112623
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of intravenous conivaptan in subjects with hepatic or renal impairment.
Roy MJ; Erdman KA; Abeyratne AT; Plumb LC; Lasseter K; Riff DS; Keirns JJ
Clin Pharmacokinet; 2013 May; 52(5):385-95. PubMed ID: 23456393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
